Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
cerebral palsy market insight

SALE

Cerebral Palsy - Market Insight, Epidemiology and Market Forecast 2030

Published Date : 2021

Pages : 158

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
Companies
- Sample Request

cerebral palsy market insight

DelveInsight's "Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cerebral Palsy, historical and forecasted epidemiology as well as the Cerebral Palsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Cerebral Palsy market report provides current treatment practices, emerging drugs, Cerebral Palsy market share of the individual therapies, current and forecasted Cerebral Palsy market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Cerebral Palsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Cerebral Palsy market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2018-2030

Cerebral Palsy Disease Understanding and Treatment Algorithm

The DelveInsight’s Cerebral Palsy market report gives a thorough understanding of the Cerebral Palsy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Cerebral Palsy Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Cerebral Palsy.

Cerebral Palsy Treatment

It covers the details of conventional and current medical therapies available in the Cerebral Palsy market for the treatment of the condition. It also provides Cerebral Palsy treatment algorithms and guidelines in the United States, Europe, and Japan.

Cerebral Palsy Epidemiology

The Cerebral Palsy epidemiology section provides insights about the historical and current Cerebral Palsy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cerebral Palsy market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Cerebral Palsy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Cerebral Palsy Epidemiology

The epidemiology segment also provides the Cerebral Palsy epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cerebral Palsy Drug Chapters

The drug chapter segment of the Cerebral Palsy report encloses the detailed analysis of Cerebral Palsy marketed drugs and late-stage (Phase-III and Phase-II) Cerebral Palsy pipeline drugs. It also helps to understand the Cerebral Palsy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Cerebral Palsy Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Cerebral Palsy treatment.

Cerebral Palsy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Cerebral Palsy treatment.

Cerebral Palsy Market Outlook

The Cerebral Palsy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cerebral Palsy market trends by analyzing the impact of current Cerebral Palsy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Cerebral Palsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cerebral Palsy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cerebral Palsy market in 7MM is expected to witness a major change in the study period 2018-2030.

Key Findings

This section includes a glimpse of the Cerebral Palsy market in 7MM.

The United States Market Outlook

This section provides the total Cerebral Palsy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Cerebral Palsy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Cerebral Palsy market size and market size by therapies in Japan is also mentioned.

Cerebral Palsy Drugs Uptake

This section focuses on the rate of uptake of the potential Cerebral Palsy drugs recently launched in the Cerebral Palsy market or expected to get launched in the market during the study period 2018-2030. The analysis covers Cerebral Palsy market uptake by drugs; patient uptake by therapies; and sales of each drug.

Cerebral Palsy Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Cerebral Palsy market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cerebral Palsy Pipeline Development Activities

The Cerebral Palsy report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Cerebral Palsy companies in the market involved in developing targeted therapeutics.

Pipeline Development Activities

The Cerebral Palsy report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Cerebral Palsy emerging therapies.

Reimbursement Scenario in Cerebral Palsy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Cerebral Palsy market trends, we take KOLs and SMEs ' opinion working in the Cerebral Palsy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cerebral Palsy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cerebral Palsy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Cerebral Palsy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Cerebral Palsy epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging Cerebral Palsy therapies is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Cerebral Palsy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the Cerebral Palsy market growth

Report Highlights

In the coming years, the Cerebral Palsy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Cerebral Palsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Several major Cerebral Palsy companies are involved in developing therapies to improve the treatment outlook. The launch of emerging therapies will significantly impact the Cerebral Palsy market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cerebral Palsy
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Cerebral Palsy Report Insights

Cerebral Palsy Population
Therapeutic Approaches
Cerebral Palsy Pipeline Analysis
Cerebral Palsy Market Size and Trends
Cerebral Palsy Market Opportunities
Impact of Upcoming Cerebral Palsy Therapies

Cerebral Palsy Report Key Strengths

10 Years Forecast
7MM Coverage
Cerebral Palsy Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Cerebral Palsy Drugs Uptake

Cerebral Palsy Report Assessment

Current Cerebral Palsy Treatment Practices
Cerebral Palsy Unmet Needs
Cerebral Palsy Pipeline Product Profiles
Cerebral Palsy Market Attractiveness
Cerebral Palsy Market Drivers and Barriers

Key Questions

Market Insights:

What was the Cerebral Palsy drug class share (%) distribution in 2018 and how it would look like in 2030?
What would be the Cerebral Palsy total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Cerebral Palsy market size during the forecast period (2018-2030)?
At what CAGR, the Cerebral Palsy market is expected to grow by 7MM during the forecast period (2018-2030)?
What would be the Cerebral Palsy market outlook across the 7MM during the forecast period (2018-2030)?
What would be the Cerebral Palsy market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of the Cerebral Palsy?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Cerebral Palsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Cerebral Palsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM with respect to the pertaining Cerebral Palsy population?
Out of all 7MM countries, which country would have the highest prevalent Cerebral Palsy population during the forecast period (2018-2030)?
At what CAGR the Cerebral Palsy patient population is expected to grow in 7MM during the forecast period (2018-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Cerebral Palsy treatment in addition to the approved therapies?
What are the current treatment guidelines for the treatment of Cerebral Palsy in the USA, Europe, and Japan?
What are the Cerebral Palsy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing Cerebral Palsy therapies for better treatment outlook?
How many therapies are in-development by each company for Cerebral Palsy treatment?
How many are emerging therapies in mid-stage, and late stage of development for Cerebral Palsy treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Cerebral Palsy therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Cerebral Palsy and their status?
What are the current challenges faced in drug development?
What are the key designations that have been granted for the emerging therapies for Cerebral Palsy?
What are the global historical and forecasted market of Cerebral Palsy?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Cerebral Palsy market
To understand the future market competition in the Cerebral Palsy market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Cerebral Palsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Cerebral Palsy market
To understand the future market competition in the Cerebral Palsy market

1. Key Insights

2. Report Introduction

3. Cerebral Palsy Market Overview at a Glance

3.1. Market Share (%) Distribution of Cerebral Palsy in 2018

3.2. Market Share (%) Distribution of Cerebral Palsy in 2030

4. Executive Summary of Cerebral Palsy

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of Cerebral Palsy

6.3. Classification System of Cerebral Palsy

6.4. Signs and Symptoms of Cerebral Palsy

6.5. Risk Factors and Causes of Cerebral Palsy

6.6. Pathophysiology of Cerebral Palsy

6.7. Complications of Cerebral Palsy

7. Diagnosis of Cerebral Palsy

7.1. Diagnostic Algorithm

7.2. Screening of Newborns

7.3. Observational Diagnosis

7.4. Imaging Tests

7.5. Genetic Testing

7.6. Differential Diagnosis

8. Diagnostic Guidelines of Cerebral Palsy

8.1. National Institute for Health and Care Excellence (NICE) assessment guidelines in under 25s

8.2. Diagnostic Assessment of the Child With Cerebral Palsy – American Academy of Neurology and the Practice Committee of the Child Neurology Society

9. Current Treatment Practices: Cerebral Palsy

9.1. Treatment Algorithm of Cerebral Palsy

9.2. Drug Therapies

9.2.1. Anticholinergics

9.2.2. Anticonvulsants

9.2.3. Antidepressants

9.2.4. Antispastics

9.2.5. Anti-inflammatories

9.3. Surgery

9.4. Other treatment options

10. Treatment and Management Guidelines of Cerebral Palsy

10.1. NICE Treatment Guidelines in Adults With Cerebral Palsy

10.2. Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy - American Academy of Neurology and the Practice Committee of the Child Neurology Society

10.3. American Family Physician – Treatment guidelines

11. Epidemiology and Patient Population

11.1. Key Findings

11.2. Epidemiology of Cerebral Palsy

11.3. Epidemiology Scenario

11.3.1. Total Prevalent Cases of Cerebral Palsy

11.3.2. Total Diagnosed Cases of Cerebral Palsy

11.3.3. Total Type-specific Cases of Cerebral Palsy

12. Patient Journey

13. Key Endpoints in Cerebral Palsy Clinical Trials

14. Marketed Drugs

14.1. Dysport (abobotulinumtoxinA): Ipsen

14.1.1. Drug Description

14.1.2. Regulatory Milestones

14.1.3. Other Developmental Activities

14.1.4. Pivotal Clinical Trial

14.2. Botox (Onabotulinum toxin A): Abbvie

14.2.1. Drug Description

14.2.2. Regulatory Milestones

14.2.3. Other Developmental Activities

14.2.4. Pivotal Clinical Trial

15. Emerging Therapies

15.1. Xeomin (Incobotulinum toxin A): Merz Pharmaceuticals

15.1.1. Product Description

15.1.2. Other Developmental Activities

15.1.3. Clinical Development

15.1.4. Safety and Efficacy

15.2. Austedo (Deutetrabenazine; TEV50717): Teva Pharmaceuticals

15.2.1. Product Description

15.2.2. Other Developmental Activities

15.2.3. Clinical Development

15.3. Myobloc (RimabotulinumtoxinB): Supernus Pharmaceuticals

15.3.1. Product Description

15.3.2. Other Developmental Activities

15.3.3. Clinical Development

15.3.4. Safety and Efficacy

15.4. UDI-001: Rohto Pharmaceutical

15.4.1. Product Description

15.4.2. Clinical Development

16. Cerebral Palsy: 7 Major Market Analysis

16.1. Key Findings

16.2. Market Outlook

16.3. Market Size of Cerebral Palsy

16.3.1. Total Market Size of Cerebral Palsy

16.3.2. Market Size of Cerebral Palsy by Therapies

17. Market Access and Reimbursement

17.1. Key HTA decisions for Cerebral Palsy

17.2. Reimbursement

17.2.1. Assistance Programs

17.3. Patient Access Programs

18. KOL Views

19. Market Drivers

20. Market Barriers

21. SWOT Analysis

22. Unmet Needs

23. Appendix

23.1. Bibliography

23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of Cerebral Palsy, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Classification Based on Gross Motor Function Classification System

Table 3: Independent Risk Factors FOR Cerebral Palsy

Table 4: Total Prevalent Cases of Cerebral Palsy (in Thousands) (2018–2030)

Table 5: Total Diagnosed Cases of Cerebral Palsy (in Thousands) (2018–2030)

Table 6: Total Type-specific Cases of Cerebral Palsy (in Thousands) (2018–2030)

Table 7: Modified Ashworth Scale (MAS) Score

Table 8: Dysport Dosing by Muscle for Upper Limb Spasticity in Pediatric Patients

Table 9: Dysport Dosing by Muscle for Lower Limb Spasticity in Pediatric Patients

Table 10: Botox Dosing by Muscle for Pediatric Upper Limb Spasticity

Table 11: Botox Dosing by Muscle for Pediatric Lower Limb Spasticity

Table 12: Xeomin (Incobotulinum toxin A), Clinical Trial Description, 2021

Table 13: Austedo (Deutetrabenazine; TEV-50717), Clinical Trial Description, 2021

Table 14: Myobloc (RimabotulinumtoxinB), Clinical Trial Description, 2021

Table 15: UDI-001, Clinical Trial Description, 2021

Table 16: 7MM Market Size of Cerebral Palsy in USD Million (2018–2030)

Table 17: 7MM Market Size of Cerebral Palsy by Therapies in USD Million (2018–2030)

Table 18: Key HTA Decisions

List of Figures:

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Types of Cerebral Palsy

Figure 3: Signs and Symptoms

Figure 4: Causes and Risk Factors of Cerebral Palsy

Figure 5: Casual Factors of Cerebral Palsy Between 20 Weeks of Gestation Period

Figure 6: Main sites and Types of Genetic Variation in Cerebral Palsy

Figure 7: Diagnostic Algorithm

Figure 8: Cranial Ultrasound

Figure 9: Treatment Algorithm

Figure 10: Total Prevalent Cases of Cerebral Palsy in the 7MM (2018–2030)

Figure 11: Total Diagnosed Cases of Cerebral Palsy in the 7MM (2018–2030)

Figure 12: Total Type-specific Cases of Cerebral Palsy in the 7MM (2018–2030)

Figure 13: Botulinum Neurotoxin

Figure 14: Market Size of Cerebral Palsy in the 7MM, USD Million (2018–2030)

Figure 15: 7MM Market Size of Cerebral Palsy by Therapies in USD Million (2018–2030)

Tags:

License Type

Offer